Top Page
Fractyl Health, Inc.
(NASDAQ:GUTS)
Fractyl Health, Inc. (GUTS) vs. SPDR S&P 500 ETF (SPY)
Fractyl Health, Inc. Business Overview & Revenue Model
Fractyl Health, Inc. Earnings Call Summary
Fractyl Health, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.00K | 93.00K | 120.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -550.00K | 43.00K | 43.00K | -452.00K | -676.00K | -770.00K |
| EBITDA | -100.66M | -92.85M | -50.55M | -48.93M | -36.25M | -28.19M |
| Net Income | -99.77M | -68.69M | -77.09M | -46.45M | -38.73M | -30.48M |
Balance Sheet | ||||||
| Total Assets | 62.01M | 108.08M | 76.21M | 60.96M | 102.55M | 34.76M |
| Cash, Cash Equivalents and Short-Term Investments | 22.29M | 67.46M | 33.21M | 49.27M | 95.47M | 29.11M |
| Total Debt | 61.72M | 62.50M | 86.39M | 306.81M | 304.34M | 202.78M |
| Total Liabilities | 80.22M | 79.65M | 401.27M | 313.27M | 311.87M | 207.48M |
| Stockholders Equity | -18.21M | 28.42M | -325.06M | -252.32M | -209.32M | -172.72M |
Cash Flow | ||||||
| Free Cash Flow | -82.34M | -67.29M | -43.18M | -46.30M | -33.51M | -31.07M |
| Operating Cash Flow | -81.35M | -65.52M | -42.82M | -46.24M | -33.46M | -31.07M |
| Investing Cash Flow | -992.00K | -1.76M | -359.00K | -56.00K | -51.00K | -2.00K |
| Financing Cash Flow | 1.88M | 101.23M | 27.44M | 4.35M | 99.88M | 54.39M |
Fractyl Health, Inc. Technical Analysis
Fractyl Health, Inc. Risk Analysis
Fractyl Health, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $336.42M | 3.57 | 108.21% | ― | 18.01% | 306.76% | |
55 Neutral | $6.43B | -2.52 | -4.30% | 5.96% | 15.30% | 11.62% | |
54 Neutral | $57.89M | 33.97 | 6.61% | ― | 21.75% | ― | |
50 Neutral | $57.83M | ― | -156.16% | ― | ― | 25.26% | |
45 Neutral | $59.96M | ― | -195.55% | ― | -0.11% | 43.47% | |
42 Neutral | $70.11M | ― | -379.75% | ― | -85.71% | 66.38% | |
40 Underperform | $74.19M | ― | -45.57% | ― | ― | -61.41% |
Fractyl Health, Inc. Corporate Events
On August 6, 2025, Fractyl Health, Inc. entered into an underwriting agreement with Ladenburg Thalmann & Co. Inc. for an offering of 19,047,619 shares of common stock and associated warrants, raising approximately $20.7 million in net proceeds. The company plans to use these funds to support its pipeline programs and general corporate purposes, with potential additional proceeds from warrant exercises. The offering closed on August 7, 2025, and includes conditions for warrant exercises and stockholder approvals, impacting the company’s financial strategy and stakeholder engagement.
On June 23, 2025, Fractyl Health, Inc. announced positive 3-month data from the REVEAL-1 cohort of its REMAIN-1 pivotal study, indicating that its Revita procedure may help maintain or further weight loss after GLP-1 therapy discontinuation. The study showed that 12 of 13 participants maintained or lost weight, with no serious adverse effects reported. Additionally, Fractyl presented promising preclinical data on its Rejuva Smart GLP-1 pancreatic gene therapy platform, which prevented obesity and hyperglycemia in animal models. These findings support further development of Fractyl’s metabolic disease therapies, with upcoming data readouts expected to reinforce Revita’s potential in post-GLP-1 weight maintenance.
On June 18, 2025, Fractyl Health, Inc. announced the issuance of two new U.S. patents that enhance its intellectual property portfolio, which protects its duodenal resurfacing innovations. These patents, issued on May 20 and June 17, 2025, are directed towards ablating duodenal mucosa using various forms of energy, reinforcing Fractyl’s leadership in metabolic disease treatment. The announcement underscores Fractyl’s commitment to advancing gut-targeted therapies for obesity and type 2 diabetes, with its lead product candidate, Revita, being a first-in-class treatment designed to remodel the duodenal lining. The company is also preparing for key data readouts from its ongoing pivotal study of Revita, which may demonstrate its potential in maintaining weight loss and supporting durable metabolic outcomes.
On June 11, 2025, Fractyl Health, Inc. held its Annual Meeting of Stockholders, with approximately 70.38% of the company’s common stock voting power represented. During the meeting, William W. Bradley, Ajay Royan, and Amy W. Schulman were elected as Class I directors for a three-year term, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
On May 19, 2025, Fractyl Health, Inc. announced the submission of the first module of its Clinical Trial Application in Europe for RJVA-001, a gene therapy candidate from its Rejuva platform. This marks a significant step in advancing their novel approach to treating type 2 diabetes and obesity by targeting pancreatic beta cells to enable physiologic hormone secretion. The upcoming Phase 1/2 study will assess the safety, tolerability, and preliminary efficacy of RJVA-001, potentially transforming diabetes treatment from daily management to a one-time therapy. If successful, this could significantly impact the company’s operations and industry positioning by offering a commercially viable path to durable disease remission.
On May 17, 2025, Fractyl Health, Inc. announced new preclinical data from its Rejuva smart GLP-1 gene therapy platform at the ASGCT 2025 Annual Meeting. The data highlighted RJVA-001’s potential to deliver durable, nutrient-responsive GLP-1 secretion from pancreatic beta cells, mimicking natural hormone regulation with low systemic GLP-1 levels. This suggests a significant advantage over current GLP-1 drugs, and the therapy demonstrated strong efficacy, targeted delivery, and a favorable safety profile. The company plans to submit the first Clinical Trial Application for RJVA-001 by June 2025, advancing towards first-in-human studies.